Hsbc Holdings PLC Sells 19,747 Shares of Thermo Fisher Scientific Inc. $TMO

Hsbc Holdings PLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 806,928 shares of the medical research company’s stock after selling 19,747 shares during the quarter. Hsbc Holdings PLC owned 0.22% of Thermo Fisher Scientific worth $468,104,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Assetmark Inc. lifted its stake in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after buying an additional 7,023 shares during the last quarter. Mackenzie Financial Corp grew its stake in Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after buying an additional 62,790 shares during the last quarter. Factory Mutual Insurance Co. raised its holdings in Thermo Fisher Scientific by 2.6% in the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock valued at $47,985,000 after acquiring an additional 2,500 shares during the period. North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $7,505,000. Finally, ICICI Prudential Asset Management Co Ltd boosted its holdings in shares of Thermo Fisher Scientific by 51.2% during the third quarter. ICICI Prudential Asset Management Co Ltd now owns 17,720 shares of the medical research company’s stock worth $8,595,000 after acquiring an additional 6,000 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $608.95.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $465.98 on Friday. The firm has a market cap of $173.17 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.06 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock’s fifty day moving average price is $476.59 and its two-hundred day moving average price is $523.32. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the company posted $5.15 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.